Clinical Trial Update: A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM) [Phase 2]

View source ↗

Summary

Phase 2 trial update for filanesib in relapsed/refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Filanesib (filanesib)

Snippet

Sponsor: Pfizer | Conditions: Advanced Multiple Myeloma | Phase 2 | Status: COMPLETED